A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors | MicrobiomeTrials← Back to trialsNCT07361562
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2025-12-30Est. Completion: 2028-05
Enrollment target: 100 participants Locations- HonorHealth Research Institute, Scottsdale, Arizona, United States
- Mayo Scottsdale, Scottsdale, Arizona, United States
- Yale Cancer Center, New Haven, Connecticut, United States
- Mayo Jacksonville, Jacksonville, Florida, United States
- Northwestern University, Chicago, Illinois, United States
- LSU Health Sciences Center School of Medicine, New Orleans, Louisiana, United States
- START Midwest, Grand Rapids, Michigan, United States
- Mayo Rochester, Rochester, Minnesota, United States
- Washington University School of Medicine - Siteman Cancer Center, St Louis, Missouri, United States
- START NY Long Island, Lake Success, New York, United States
- NYU Langone, New York, New York, United States
- Tennessee Oncology, Nashville, Tennessee, United States
- NEXT Oncology Texas, Austin, Texas, United States
- START Mountain Region, West Valley City, Utah, United States
- NEXT Oncology Virginia, Fairfax, Virginia, United States
Other microbiome trials you might be interested in
Advanced Solid Tumor
The purpose of this study is to evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary …
Birmingham, United StatesEst. completion Nov 1, 2028
Advanced Solid TumorLocally Advanced Solid TumorMetastatic Solid TumorPlatinum-resistant Ovarian CancerPost Anti-PD-1 Melanoma2L+ Cervical Cancer
Neoadjuvant Melanoma
Neoadjuvant Non-Small Cell Lung Cancer
Post Anti-PD-(L)1 Non-Small Cell Lung Cancer
Post Anti-PD-(L)1 Small Cell Lung Cancer
Third Line or Later (3L+) HER2+ Breast Cancer
Second or Third Line (2L/3L) Cervical Cancer
Third-line or Later (3L+) Platinum-resistant Ovarian Cancer (PROC)
TransCon IL-2 β/γ is an investigational drug being developed for treatment of locally advanced or metastatic solid tumor…
Los Angeles, United StatesEst. completion Aug 2027
Adult Solid Neoplasm
This phase I trial studies the side effects and best dose of ixabepilone and temsirolimus in treating patients with soli…
Jacksonville, United StatesEst. completion Jun 26, 2018